A CCR-5 antagonist inhibits the development of adjuvant arthritis in rats

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Sir, Chemokine receptor CCR5 is preferentially expressed on Th1 lymphocytes and has been reported to have important roles in the pathogenesis of rheumatoid arthritis (RA). Yang et al. [1] demonstrated that a CCR5 antagonist inhibits the development of arthritis in the collagen-induced arthritis (CIA) model in mice. They showed that the inhibition of the development of arthritis is not caused by affecting the generation of collagen-sensitized T cells but by interfering with their migration to joint lesions. Recently, Vierboom et al. [2] reported the interesting finding that a CCR5 antagonist inhibited the development of CIA in rhesus monkeys. They showed that systemic administration of a small molecular weight antagonist of CCR5, SCH-X, suppressed the development of CIA in a monkey model of rheumatoid arthritis (RA).

This publication has 9 references indexed in Scilit: